enVVeno Medical Corporation (NVNO)
NVNO moved a median of -0.14% 30 minutes after news, and +0.20% by the close. How NVNO actually reacts to news — the realized, point-in-time move the market made, measured across 172 labeled events over the last three years with zero look-ahead.
NVNO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 150 |
| 30-min | -0.14% | 47% | 163 |
| 60-min | +0.20% | 51% | 167 |
| to close | +0.20% | 51% | 171 |
| Middle 50% of NVNO reactions | -1.91% to +2.28% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 172 |
Half of all enVVeno Medical Corporation news events land between -1.91% and +2.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NVNO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NVNO's baseline. Nothing else.
Recent NVNO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial | Press release | ACCESS Newswire | +0.00% | -0.12% | |
| enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series | Press release | ACCESS Newswire | +0.39% | -3.52% | |
| enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand | Press release | ACCESS Newswire | — | -6.42% | |
| enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference | Press release | ACCESS Newswire | — | -0.18% | |
| Form S-3 enVVeno Medical Corp | SEC filing · Form S-3 | SEC EDGAR | — | +0.10% | |
| Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments | Press release | ACCESS Newswire | +3.05% | +6.19% | |
| enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve | Press release | ACCESS Newswire | — | +0.76% | |
| Form 10-Q enVVeno Medical Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.76% | |
| enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment | Press release | ACCESS Newswire | — | +0.37% | |
| Form 8-K enVVeno Medical Corp For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | — | +0.37% | |
| enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial | Press release | ACCESS Newswire | -1.16% | -1.87% | |
| enVVeno Medical to Present in the Webull Corporate Connect Webinar Series | Press release | ACCESS Newswire | — | +3.25% | |
| enVVeno Medical to Participate in the Virtual Investor Closing Bell Series | Press release | ACCESS Newswire | — | +0.75% | |
| enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment | Press release | ACCESS Newswire | +4.49% | -2.61% | |
| enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System | Press release | ACCESS Newswire | — | +1.49% | |
| Form 10-Q enVVeno Medical Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +1.49% | |
| enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve | Press release | ACCESS Newswire | -0.09% | -7.27% | |
| Form 8-K enVVeno Medical Corp For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -7.27% | |
| enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System | Press release | ACCESS Newswire | +0.00% | +1.83% | |
| Form 10-K enVVeno Medical Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.83% | |
| Form S-8 enVVeno Medical Corp | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +1.83% | |
| enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | ACCESS Newswire | — | -8.66% | |
| Form 8-K enVVeno Medical Corp For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | — | -8.66% | |
| Form 8-K enVVeno Medical Corp For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +1.90% | -1.18% | |
| enVVeno Medical Announces Reverse Stock Split | Press release | ACCESS Newswire | -1.49% | -6.42% | |
| Form 8-K enVVeno Medical Corp For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -3.03% | -4.85% | |
| Form DEFR14A enVVeno Medical Corp | SEC filing · Form DEFR14A | SEC EDGAR | -0.44% | +9.25% | |
| enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment | Press release | ACCESS Newswire | +1.25% | -5.58% | |
| Form 8-K enVVeno Medical Corp For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | -5.93% | +1.24% | |
| Form PRER14A enVVeno Medical Corp | SEC filing · Form PRER14A | SEC EDGAR | +2.96% | +2.74% | |
| Form 8-K enVVeno Medical Corp For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -3.42% | +5.00% | |
| enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -3.92% | +8.71% | |
| Form 10-Q enVVeno Medical Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.92% | +8.71% | |
| Form 8-K enVVeno Medical Corp For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | -3.92% | +8.71% | |
| Form DEF 14A enVVeno Medical Corp For: Dec 11 | SEC filing · Form DEF | SEC EDGAR | -3.92% | +8.71% | |
| Form DEFA14A enVVeno Medical Corp | SEC filing · Form DEFA14A | SEC EDGAR | -3.92% | +8.71% | |
| Form 8-K enVVeno Medical Corp For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | -13.74% | |
| enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment | Press release | ACCESS Newswire | -1.03% | -0.11% | |
| enVVeno Medical Updates Regulatory Status of VenoValve(R) | Press release | ACCESS Newswire | -2.38% | +7.81% | |
| enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) | Press release | ACCESS Newswire | +12.50% | -2.50% | |
| Form 8-K enVVeno Medical Corp For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +12.50% | -2.50% | |
| enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | Press release | ACCESS Newswire | +0.22% | +8.87% | |
| Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency | Press release | ACCESS Newswire | +0.31% | +2.04% | |
| enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company | Press release | ACCESS Newswire | +2.04% | -1.22% | |
| enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +1.86% | +6.80% | |
| Form 10-Q enVVeno Medical Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.86% | +6.80% | |
| enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference | Press release | ACCESS Newswire | -0.40% | -3.97% | |
| Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting | Press release | ACCESS Newswire | +0.28% | +6.98% | |
| Form 8-K enVVeno Medical Corp For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | -8.71% | |
| enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer | Press release | ACCESS Newswire | +0.00% | +0.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NVNO section they belong to.
Where else NVNO is measured.
NVNO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is enVVeno Medical Corporation's median reaction calculated?
Every labeled NVNO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 172 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of NVNO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NVNO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.